Faced with generic competition to big-selling drugs, Eli Lilly (LLY) plans to cut 3,500 jobs — or 8.5 percent of its global workforce – in hopes of saving $500 million annually.

Most of the cuts will occur in the U.S. through a voluntary early retirement program, although layoffs will take place as facilities are closed, such as research and development centers in Shanghai, China, and Bridgewater, N.J. Lilly currently employs about 41,000 people worldwide.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • 1) Lechleiter picked the right time to quit.

    2) Put all your eggs in the AZ basket and you see the result.

    3) Fret not, Lilyputians, you will get a great package. My wife’s severance was actually more than my salary when benefits were included. Hopefully you will get some free ducats to the Lily Corporate Center cafeteria. Best coffee in pharma.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy